Ravindra Majeti Net Worth
The estimated Net Worth of Ravindra Majeti is at least $13.8 Million dollars as of 15 May 2019. Mr. Majeti owns over 4,311 units of Forty Seven stock worth over $11,385,414 and over the last few years he sold FTSV stock worth over $2,394,898. In addition, he makes $0 as Independent Director at Forty Seven.
Mr. Majeti FTSV stock SEC Form 4 insider trading
Ravindra has made over 6 trades of the Forty Seven stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,311 units of FTSV stock worth $69,062 on 15 May 2019.
The largest trade he’s ever made was selling 35,000 units of Forty Seven stock on 15 March 2019 worth over $624,050. On average, Ravindra trades about 24,052 units every 20 days since 2019. As of 15 May 2019 he still owns at least 1,421,400 units of Forty Seven stock.
You can see the complete history of Mr. Majeti stock trades at the bottom of the page.
Ravindra Majeti biography
Ravindra Majeti is Independent Director of the Company. Dr. Majeti served in various positions at Stanford University, including as an Associate Professor in the Department of Medicine, Division of Hematology, since November 2015, and as an Assistant Professor in the Department of Medicine, Division of Hematology, from 2009 to November 2015. He received an A.B. in Biochemical Sciences from Harvard University, a Ph.D. and an M.D. from the University of California, San Francisco and completed a residency in internal medicine at Brigham and Women’s Hospital. Dr. Majeti completed a Fellowship in Hematology at Stanford University.
How old is Ravindra Majeti?
Ravindra Majeti is 45, he’s been the Independent Director of Forty Seven since 2015. There are 9 older and no younger executives at Forty Seven. The oldest executive at Forty Seven, Inc. is Irving Weissman, 78, who is the Independent Director.
What’s Ravindra Majeti’s mailing address?
Ravindra’s mailing address filed with the SEC is C/O FORTY SEVEN, INC., 1490 O’BRIEN DRIVE, SUITE A, MENLO PARK, CA, 94025.
Insider trading at Forty Seven
Over the last few years, insiders at Forty Seven have traded over $4,118,522 worth of Forty Seven stock and bought 2,621,245 units worth $41,666,515 . The most active insider traders include Tench Coxe, Michael L Speiser, and Jeffrey W Bird. On average, Forty Seven executives and independent directors trade stock every 7 days with the average trade being worth of $569,591. The most recent stock trade was executed by Mark Anthony Mc Camish on 20 May 2019, trading 16,500 units of FTSV stock currently worth $80,520.
What does Forty Seven do?
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
What does Forty Seven’s logo look like?
Complete history of Mr. Majeti stock trades at Forty Seven
Forty Seven executives and stock owners
Forty Seven executives and other stock owners filed with the SEC include:
- Mark McCamish, President, Chief Executive Officer, Director
- Ann Rhoads, Chief Financial Officer
- Chris Takimoto, Chief Medical Officer
- Ian Clark, Independent Director
- Craig Gibbs, Chief Business Officer
- Kristine Ball, Independent Director
- Jeffrey Bird, Lead Independent Director
- Dennis Henner, Independent Director
- Ravindra Majeti, Independent Director
- Irving Weissman, Independent Director
- Samuel J Iii Pullara,
- Harbor Master Investors (Ca…, 10% owner
- Michael L Speiser, 10% owner
- Stefan A Dyckerhoff,
- Venture Partners X, L.P.Lig…,
- Hill Ventures Sutter,
- Peter Nieh, 10% owner
- Christopher J Schaepe, Director
- Tench Coxe, 10% owner
- Dennis Henner, Director
- James N White, 10% owner
- Venture Partners Select Ii,…,
- Ravi Mhatre, 10% owner